Program Overview:
Iron deficiency (ID) is common in patients with heart failure (HF), and ID is
increasingly recognized as an important comorbidity in HF, even in the
absence of anemia. ID is independently associated with worse functional
capacity, lower quality of life (QOL), and an increased risk for hospitalization
and mortality. Although HF guidelines recommend regular screening for ID
with iron studies (serum iron, ferritin, transferrin saturation (TSAT), these
studies are often not conducted, and therefore ID is underdiagnosed.
Consequently, HF patients with ID are undertreated. Oral iron is ineffective
in HF patients and is not recommended in HF guidelines. Conversely,
intravenous (IV) repletion of iron has been shown to improve exercise
capacity and QOL and is recommended in HF guidelines. Furthermore, IV
iron supplementation with the ferric carboxymaltose (FCM) formulation
reduces HF and cardiovascular (CV) hospitalizations as demonstrated in a
meta-analysis of over 4,000 patients. Numerous potential barriers to
diagnosis of ID and treatment with IV iron can be present, and therefore a
multidisciplinary team effort involving physicians, nurses, and pharmacists
can ensure that challenges are satisfactorily addressed. Therefore, in this
educational initiative, to take place at the 2024 Heart Failure Society of
America annual meeting, attendees will be provided with information on the
detrimental impact of ID in patients with HF, tests for screening for ID, a
definition to determine a diagnosis of ID, and evidence demonstrating the
benefits achieved with IV iron therapy. A case study will focus on overcoming
challenges in HF patient care with multidisciplinary teamwork, following
best practices outlined in an expert-generated algorithm published in a
scientific statement from the Heart Failure Society of America (HFSA).
|
|
Educational Objectives:
Recognize the deleterious consequences of iron deficiency, with or
without anemia, in HF
Describe the importance of regular screening for iron deficiency in HF
patients
Identify the drawbacks of, and explain evidence associated with oral
iron supplementation for treating iron deficiency in HF
Interpret clinical evidence with intravenous iron therapy for iron
deficiency in patients with HF
Identify potential challenges to diagnosing and treating iron deficiency
in HF patients and recognize the effective contributions made by multi-
disciplinary healthcare personnel in addressing these challenges
Target Audience:
This educational activity is intended for clinicians who manage patients
with heart failure.
Accreditation & Credit Designation:
Voxmedia LLC is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide continuing
medical education for physicians.
Voxmedia LLC designates this live activity for a maximum of 1.0 AMA PRA Category
Credit(s) ™. Physicians should claim only the credit commensurate with the extent
of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a
certificate of completion as AANP accepts AMA PRA Category 1.0 Credits ™
through its reciprocity agreements.
The National Commission on Certification of Physician Assistants accepts AMA
PRA Category 1.0 Credits ™ through its reciprocity agreements.
Educational Grant: Voxmedia International gratefully acknowledges the independent educational grant provided by American Regent.
Disclosure Statement:
Voxmedia strives to ensure fair-balance, independence, objectivity,
and scientific rigor in all directly or jointly sponsored educational
activities. All prospective faculty are required to disclose to Voxmedia
all financial relationships for the preceding 24 months (1) with any
commercial interest producing, marketing, re-selling, or distributing
health care goods or services consumed by, or used on, patients AND
(2) with any commercial supporters prior to participating in the
planning of an activity or developing content. Only after Voxmedia
mitigates all financial relationships may faculty receive approval to
participate, and are expected to contribute evidence-based material.
Faculty are required to indicate areas of their presentation that are
based on professional opinion vs. guidelines, meta-analysis. All
information submitted will be peer-reviewed. The intent of this
disclosure is not to prevent faculty from participating, but rather to
provide learners with information on which they can make their own
judgment of commercial bias. Voxmedia will disclose to learners that
all relevant financial relationships have been mitigated in either
written materials, visually and/or verbally. It remains for the audience
to determine whether the speaker s interests or relationships may
influence the presentation. Speakers must make a
meaningful disclosure to the audience of their
discussions of any unlabeled or investigational
use(s) of drugs or devices.
|
